

April 26th, 2024

Luxna Announces Collaboration Expansion with Servier

Osaka, Japan, April 26th, 2024 - Luxna Biotech Co., Ltd. (President CEO: Hideaki Sato, Headquarters: Suita-shi, Osaka, Japan, hereinafter "Luxna") today announced that it has expanded the current ongoing collaboration with Servier, a global pharmaceutical group, (President: Olivier Laureau, Headquarters: Suresnes, France, hereinafter "Servier") for drug discovery research in the field of neurological diseases.

Luxna and Servier entered into a first collaboration and option agreement for drug discovery research in the field of neurological diseases in 2023, for the development of transformative therapies, and the parties will now expand this strategic alliance on multiple target genes.

Under the new collaboration agreement, Luxna and Servier will continue to work together to optimize specific antisense oligonucleotides (hereinafter "ASO") compounds directed against transformative therapeutic targets in neurological diseases using Luxna's breakthrough xeno nucleic acid technology (hereinafter "Luxna XNAs Technology") directed against a new target gene.

As a result of this expansion, Luxna will receive an upfront payment, and upon successful achievement of the first stage, Luxna will be eligible for further milestone payments from Servier .

Hideaki Sato, President CEO of Luxna, commented as follows: "We have been pursuing the application of Luxna XNAs Technology to the field of neurological diseases and have enhanced our ASO drug discovery platform called LuxiAP™. We are very pleased that our efforts have been now recognized and that we have expanded our strategic alliance with Servier. The expanded partnership with Servier will accelerate the development and practical application of oligonucleotide therapies using Luxna XNAs Technology."

About Luxna XNAs Technology

Luxna XNAs Technology collectively means an innovative nucleic acid group of AmNA™, scpBNA™, GuNA™ and 5'-CP™ originated in Professor Obika's laboratory at the Osaka University Graduate School of Pharmaceutical Sciences, Bioorganic Chemistry. Luxna XNAs



April 26th, 2024

Technology could make available ASOs with high activity and low toxicity, by taking advantage of its characteristics of strong binding to mRNA and/or reduced toxicity.

About Luxna Biotech Co., Ltd.

Luxna is a biotech founded to develop safer and more effective oligonucleotide therapies (OTs) for practical use using the drug discovery platform based on modified nucleic acids originated at Osaka University. Our purpose is to bring OTs for patients with difficult-to-treat diseases. We actively collaborate with several pharmaceutical companies in developing new and effective OTs as well as advancing our own.

Contact

Luxna Biotech Co., Ltd.

E-mail: info@luxnabiotech.co.jp HP : <https://luxnabiotech.co.jp/>